Next-generation CAR T and TCR T cell therapies for prostate cancer, Ewing sarcoma and leukemia

Partnered Development

We work closely with Fred Hutch and MSK to move preclinically evaluated programs into the clinic. Fred Hutch conducts our clinical trials under agreements funded by PromiCell, and the National Cancer Institute manufactures our lead program.

Key Programs

PRO CAR-201
STEAP1 CAR T

  • Metastatic castration-resistant prostate cancer and Ewing sarcoma

  • Licensed from Fred Hutch

PRO CAR-202
IL-18-armored STEAP1 CAR T

  • Metastatic castration-resistant prostate cancer

  • Licensed from Fred Hutch

PRO TCR-401
HA-1 TCR T

  • Acute leukemia relapsed after stem cell transplant

  • Licensed from Fred Hutch

PRO CAR-301
CD33 CAR T

  • Acute myeloid leukemia

  • Licensed from MSK

Email us:

info@promicell.com

Address

3350 Virginia Street Miami, FL 33133, USA

Legal

Privacy PolicyWebsite Terms
This website contains forward-looking statements, includingstatements regarding the development of our product candidates. Thesestatements are based on current expectations and are subject to risks anduncertainties. Actual results may differ materially. We undertake no obligationto update these statements except as required by law.
© 2026 PromiCell, Inc. All rights reserved. Powered by The Smiling Hippo

We're Updating Our Website

Our website is temporarily unavailable while we make some important improvements.

We'll be back shortly. Thank you for your patience.